Trials / Completed
CompletedNCT00553696
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
A Phase 1 Study Of Sunitinib In Combination With S-1 And Cisplatin In Patients With Advanced Or Metastatic Gastric Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin | Cisplatin 60 mg/m2 on day 1 of each 28 day cycle |
| DRUG | S-1 | S-1 80 mg/m2 on days 1-21 of each 28 day cycle |
| DRUG | Sunitinib | Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-07-01
- Completion
- 2014-03-01
- First posted
- 2007-11-05
- Last updated
- 2015-03-13
- Results posted
- 2015-03-13
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00553696. Inclusion in this directory is not an endorsement.